Literature DB >> 3770055

Treatment of hairy-cell leukemia with recombinant alpha 2-interferon.

Z N Berneman, G Gastl, D Gangji, B van Camp, K Jochmans, W Aulitzky, J Flament, M E Peetermans, C Huber.   

Abstract

Eleven patients with hairy-cell leukemia (eight with progressive and three with non-progressive disease) were treated with low dose recombinant human alpha 2-interferon. After a 3-month treatment period, nine patients showed an improvement and one patient a partial remission. By then, transfusions were not required any more and serious infections were no longer encountered. Four patients were further treated: three for a total period of 9 months and one for 6 months; all of them reached a partial or complete remission. The treatment was equally effective in patients with both progressive and non-progressive disease. Previous absence of response to splenectomy did not preclude a positive effect of IFN therapy. In two patients, IFN dose reduction was necessary due to unremitting flu-like symptoms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770055     DOI: 10.1016/0277-5379(86)90066-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 2.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

3.  Similar biological effects of different low doses of interferon alpha in cancer patients.

Authors:  C Billard; R A Diez; D Ferbus; N Raynaud; T Dorval; P Pouillart; K Nielsen; E Falcoff
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.